🔍 MilliporeSigma, the life science business of Merck KGaA, has agreed to acquire Mirus Bio for $600 million.
😮 Mirus Bio specializes in transfection reagents used in the production of viral vector-based gene therapies.
💪 This acquisition will strengthen MilliporeSigma’s portfolio and position in the growing cell and gene therapy market.
📆 The deal is expected to close in the third quarter of 2024.
😮 Mirus Bio specializes in transfection reagents used in the production of viral vector-based gene therapies.
💪 This acquisition will strengthen MilliporeSigma’s portfolio and position in the growing cell and gene therapy market.
📆 The deal is expected to close in the third quarter of 2024.
📢 MilliporeSigma’s $600M Acquisition Boosts Cell Therapy Portfolio
Introduction:
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, has signed a definitive agreement to acquire Mirus Bio for $600 million. Mirus Bio specializes in the development and commercialization of transfection reagents that enhance the production of viral vector-based gene therapies.
Main points:
- MilliporeSigma has announced the acquisition of Mirus Bio for $600 million.
- Mirus Bio specializes in the development of transfection reagents that enhance viral vector-based gene therapy production.
- The acquisition strengthens MilliporeSigma’s upstream portfolio in viral vector manufacturing.
- Viral vector-based cell and gene therapies are projected to experience significant growth.
- The acquisition will allow Mirus Bio to reach more customers and patients globally.
Conclusion:
MilliporeSigma’s acquisition of Mirus Bio for $600 million expands its capabilities in viral vector-based gene therapy production. This acquisition not only strengthens MilliporeSigma’s upstream portfolio but also aligns with the projected growth of viral vector-based cell and gene therapies. By combining their expertise, MilliporeSigma and Mirus Bio aim to serve more customers and ultimately benefit patients worldwide.
